Figure 5
Effect of treatment with anti-interleukin (IL)-10 antibody alone or with anti-TGF-β (anti-transforming growth factor-β) antibody during primary infection on secondary gonococcal infection in BALB/c mice. (a) Time course of secondary infection in mice treated with anti-IL-10 antibody, anti-IL-10 plus anti-TGF-β, or control immunoglobulin G (IgG) during primary infection or in previously sham-infected mice with or without anti-IL-10 treatment; n=8 mice per group. (b) Flow cytometric analysis of cytokine expression in iliac lymph node CD4+ T cells isolated at day 5 from previously sham-infected or from reinfected mice treated with anti-IL-10 antibody or control IgG during primary infection; n=8 mice per group. (c) Reverse transcriptase–PCR (RT-PCR) analysis of interferon (IFN)-γ, IL-4, and IL-17 mRNA levels in vaginas harvested at day 3 from previously sham-infected or from reinfected mice treated with anti-IL-10 antibody or control IgG during primary infection; n=7 mice per group. Cytokine gene expression levels detected by RT-PCR were normalized relative to expression of β-actin and set at 1.0 for unstimulated cells. All data shown are representative of three independent experiments. *P<0.01 anti-IL-10 vs. control IgG treatments. Ngo, Neisseria gonorrhoeae.
